Swedish Orphan Biovitrum (BIOVF) – What Are Investment Firms Thinking About This Stock?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has earned a consensus rating of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company.

A number of research analysts have recently commented on BIOVF shares. Pareto Securities raised shares of Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a report on Tuesday. Nordea Equity Research lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, October 22nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Finally, HC Wainwright restated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Wednesday.

Swedish Orphan Biovitrum Stock Performance

Swedish Orphan Biovitrum stock opened at $45.72 on Friday. Swedish Orphan Biovitrum has a 12-month low of $34.88 and a 12-month high of $49.03. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 0.20. The business’s 50-day moving average price is $46.06 and its two-hundred day moving average price is $44.21. The stock has a market cap of $16.27 billion, a PE ratio of 22.74 and a beta of 0.47.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.